Platelets as delivery systems for disease treatments

Advanced Drug Delivery Reviews

Volumn 62, Issue 12, 2010, Pages 1196-1203

  Shi, Qizhen ^a   Montgomery, Robert R ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Gene therapy; Hemostasis; Platelet; Platelet specific promoter

Indexed keywords

BIOLOGICAL MOLECULE; BIOLOGICALLY ACTIVE MOLECULES; BLEEDING DISORDER; BLOOD CELLS; DELIVERY SYSTEMS; DISEASE TREATMENT; GENETIC THERAPY; HEMOPHILIA A; HEMOSTASIS; LOGICAL APPROACHES; PATHOPHYSIOLOGIC;

BLOOD; DISEASES; GENE THERAPY; GENETIC ENGINEERING;

PLATELETS;

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IB BETA; GLYCOPROTEIN IIIA; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

BERNARD SOULIER DISEASE; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC MANIPULATION; GLANZMANN DISEASE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MEGAKARYOCYTE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; STEM CELL GENE THERAPY; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; CYTOPLASMIC GRANULES; FACTOR VIII; GENE THERAPY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMANS; MEGAKARYOCYTES; PLATELET COUNT;

EID: 78649321428     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.06.007     Document Type: Review

References (148)

1. Blair P., Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009, 23:177-189.
2. Odell T.T., Jackson C.W. Polyploidy and maturation of rat megakaryocytes. Blood 1968, 32:102-110.
3. Odell T.T., Jackson C.W., Friday T.J. Megakaryocytopoiesis in rats with special reference to polyploidy. Blood 1970, 35:775-782.
4. EBBE S., STOHLMAN F. Megakaryocytopoiesis in the rat. Blood 1965, 26:20-35.
5. Tomer A., Harker L.A., Burstein S.A. Purification of human megakaryocytes by fluorescence-activated cell sorting. Blood 1987, 70:1735-1742.
6. Tomer A., Harker L.A., Burstein S.A. Flow cytometric analysis of normal human megakaryocytes. Blood 1988, 71:1244-1252.
7. Breton-Gorius J., Reyes F. Ultrastructure of human bone marrow cell maturation. Int. Rev. Cytol. 1976, 46:251-321.
8. EBBE S. Biology of megakaryocytes. Prog. Hemost. Thromb. 1976, 3:211-229.
9. Nakao K., Angrist A.A. Membrane surface specialization of blood platelet and megakaryocyte. Nature 1968, 217:960-961.
10. Italiano J.E., Lecine P., Shivdasani R.A., Hartwig J.H. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J. Cell Biol. 1999, 147:1299-1312.
11. Italiano J.E., Shivdasani R.A. Megakaryocytes and beyond: the birth of platelets. J. Thromb. Haemost. 2003, 1:1174-1182.
12. Patel S.R., Hartwig J.H., Italiano J.E. The biogenesis of platelets from megakaryocyte proplatelets. J. Clin. Invest. 2005, 115:3348-3354.
13. Zucker-Franklin D., Petursson S. Thrombocytopoiesis-analysis by membrane tracer and freeze-fracture studies on fresh human and cultured mouse megakaryocytes. J. Cell Biol. 1984, 99:390-402.
14. Mori M., Tsuchiyama J., Okada S. Proliferation, migration and platelet release by megakaryocytes in long-term bone marrow culture in collagen gel. Cell Struct. Funct. 1993, 18:409-417.
15. Caine Y.G., Vlodavsky I., Hersh M., Polliack A., Gurfel D., Or R., Levine R.F., Eldor A. Adhesion, spreading and fragmentation of human megakaryocytes exposed to subendothelial extracellular matrix: a scanning electron microscopy study. Scan. Electron Microsc. 1986, 1087-1094.
16. Deutsch V.R., Olson T.A., Nagler A., Slavin S., Levine R.F., Eldor A. The response of cord blood megakaryocyte progenitors to IL-3, IL-6 and aplastic canine serum varies with gestational age. Br. J. Haematol. 1995, 89:8-16.
17. Kosaki G. Platelet production by megakaryocytes: protoplatelet theory justifies cytoplasmic fragmentation model. Int. J. Hematol. 2008, 88:255-267.
18. Kosaki G. In vivo platelet production from mature megakaryocytes: does platelet release occur via proplatelets?. Int. J. Hematol. 2005, 81:208-219.
19. Zucker-Franklin D. The submembranous fibrils of human blood platelets. J. Cell Biol. 1970, 47:293-299.
20. Choi E.S., Nichol J.L., Hokom M.M., Hornkohl A.C., Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995, 85:402-413.
21. Long M.W. Megakaryocyte differentiation events. Semin. Hematol. 1998, 35:192-199.
22. Harker L.A., Finch C.A. Thrombokinetics in man. J. Clin. Invest. 1969, 48:963-974.
23. Stenberg P.E., Levin J. Mechanisms of platelet production. Blood Cells 1989, 15:23-47.
24. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J. Clin. Invest. 2005, 115:3339-3347.
25. Deutsch V.R., Tomer A. Megakaryocyte development and platelet production. Br. J. Haematol. 2006, 134:453-466.
26. Becker R.C., Smyth S. The evolution of platelet-directed pharmacotherapy. J. Thromb. Haemost. 2009, 7(Suppl 1):266-271.
27. Branehog I., Ridell B., Swolin B., Weinfeld A. Megakaryocyte quantifications in relation to thrombokinetics in primary thrombocythaemia and allied diseases. Scand. J. Haematol. 1975, 15:321-332.
28. Bentfeld M.E., Bainton D.F. Cytochemical localization of lysosomal enzymes in rat megakaryocytes and platelets. J. Clin. Invest. 1975, 56:1635-1649.
29. Corash L., Costa J.L., Shafer B., Donlon J.A., Murphy D. Heterogeneity of human whole blood platelet subpopulations. III. Density-dependent differences in subcellular constituents. Blood 1984, 64:185-193.
30. Vicic W.J., Weiss H.J. Evidence that platelet alpha-granules are a major determinant of platelet density: studies in storage pool deficiency. Thromb. Haemost. 1983, 50:878-880.
31. Harrison P., Cramer E.M. Platelet alpha-granules. Blood Rev. 1993, 7:52-62.
32. Tomer A. Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes. Blood 2004, 104:2722-2727.
33. Ruggeri Z.M. Platelets in atherothrombosis. Nat. Med. 2002, 8:1227-1234.
34. Parker R.I., Gralnick H.R. Identification of platelet glycoprotein IIb/IIIa as the major binding site for released platelet-von Willebrand factor. Blood 1986, 68:732-736.
35. Atri S.C., Misra J., Bisht D., Misra K. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery 1990, 108:508-512.
36. Gawaz M., Langer H., May A.E. Platelets in inflammation and atherogenesis. J. Clin. Invest. 2005, 115:3378-3384.
37. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ. Res. 2005, 96:612-616.
38. Anitua E., Andia I., Ardanza B., Nurden P., Nurden A.T. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb. Haemost. 2004, 91:4-15.
39. Klinger M.H., Jelkmann W. Role of blood platelets in infection and inflammation. J. Interferon Cytokine Res. 2002, 22:913-922.
40. Ohmori T., Kashiwakura Y., Ishiwata A., Madoiwa S., Mimuro J., Sakata Y. Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2266-2272.
41. Medin J.A., Karlsson S. Viral vectors for gene therapy of hematopoietic cells. Immunotechnology 1997, 3:3-19.
42. Medin J.A., Karlsson S. Selection of retrovirally transduced cells to enhance the efficiency of gene therapy. Proc. Assoc. Am. Physicians 1997, 109:111-119.
43. Weeratna R.D., Wu T., Efler S.M., Zhang L., Davis H.L. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther. 2001, 8:1872-1878.
44. Tronik-Le R.D., Roullot V., Schweitzer A., Berthier R., Marguerie G. Suppression of erythro-megakaryocytopoiesis and the induction of reversible thrombocytopenia in mice transgenic for the thymidine kinase gene targeted by the platelet glycoprotein alpha IIb promoter. J. Exp. Med. 1995, 181:2141-2151.
45. Poujol C., Tronik-Le R.D., Tropel P., Roullot V., Nurden A., Marguerie G., Nurden P. Ultrastructural analysis of bone marrow hematopoiesis in mice transgenic for the thymidine kinase gene driven by the alpha IIb promoter. Blood 1998, 92:2012-2023.
46. Tropel P., Roullot V., Vernet M., Poujol C., Pointu H., Nurden P., Marguerie G., Tronik-Le R.D. A 2.7-kb portion of the 5? flanking region of the murine glycoprotein alphaIIb gene is transcriptionally active in primitive hematopoietic progenitor cells. Blood 1997, 90:2995-3004.
47. Berridge M.V., Ralph S.J., Tan A.S. Cell-lineage antigens of the stem cell-megakaryocyte-platelet lineage are associated with the platelet IIb-IIIa glycoprotein complex. Blood 1985, 66:76-85.
48. Fang J., Hodivala-Dilke K., Johnson B.D., DU L.M., Hynes R.O., White G.C., Wilcox D.A. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood 2005, 106:2671-2679.
49. Shi Q., Wilcox D.A., Fahs S.A., Weiler H., Wells C.W., Cooley B.C., Desai D., Morateck P.A., Gorski J., Montgomery R.R. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J. Clin. Invest. 2006, 116:1974-1982.
50. Shi Q., Wilcox D.A., Morateck P.A., Fahs S.A., Kenny D., Montgomery R.R. Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. J. Thromb. Haemost. 2004, 2:1989-1997.
51. Shi Q., Wilcox D.A., Fahs S.A., Fang J., Johnson B.D., DU L.M., Desai D., Montgomery R.R. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J. Thromb. Haemost. 2007, 5:352-361.
52. Wilcox D.A., Olsen J.C., Ishizawa L., Griffith M., White G.C. Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc. Natl Acad. Sci. USA 1999, 96:9654-9659.
53. Wilcox D.A., Olsen J.C., Ishizawa L., Bray P.F., French D.L., Steeber D.A., Bell W.R., Griffith M., White G.C. Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood 2000, 95:3645-3651.
54. Rodriguez M.H., Enjolras N., Plantier J.L., Rea M., Leboeuf M., Uzan G., Bordet J.C., Negrier C. Expression of coagulation factor IX in a haematopoietic cell line. Thromb. Haemost. 2002, 87:366-373.
55. Yarovoi H.V., Kufrin D., Eslin D.E., Thornton M.A., Haberichter S.L., Shi Q., Zhu H., Camire R., Fakharzadeh S.S., Kowalska M.A., Wilcox D.A., Sachais B.S., Montgomery R.R., Poncz M. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood 2003, 102:4006-4013.
56. Ohmori T., Ishiwata A., Kashiwakura Y., Madoiwa S., Mitomo K., Suzuki H., Hasegawa M., Mimuro J., Sakata Y. Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets. Mol. Ther. 2008, 16:1359-1365.
57. Ohmori T., Mimuro J., Takano K., Madoiwa S., Kashiwakura Y., Ishiwata A., Niimura M., Mitomo K., Tabata T., Hasegawa M., Ozawa K., Sakata Y. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J. 2006, 20:1522-1524.
58. Ravid K., Beeler D.L., Rabin M.S., Ruley H.E., Rosenberg R.D. Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc. Natl Acad. Sci. USA 1991, 88:1521-1525.
59. Kufrin D., Eslin D.E., Bdeir K., Murciano J.C., Kuo A., Kowalska M.A., Degen J.L., Sachais B.S., Cines D.B., Poncz M. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003, 102:926-933.
60. Damon A.L., Scudder L.E., Gnatenko D.V., Sitaraman V., Hearing P., Jesty J., Bahou W.F. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice. Thromb. Haemost. 2008, 100:1111-1122.
61. Deveaux S., Filipe A., Lemarchandel V., Ghysdael J., Romeo P.H., Mignotte V. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood 1996, 87:4678-4685.
62. Kaushansky K., Drachman J.G. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 2002, 21:3359-3367.
63. Wagner C.L., Mascelli M.A., Neblock D.S., Weisman H.F., Coller B.S., Jordan R.E. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996, 88:907-914.
64. Prandini M.H., Martin F., Thevenon D., Uzan G. The tissue-specific transcriptional regulation of the megakaryocytic glycoprotein IIb gene is controlled by interactions between a repressor and positive cis-acting elements. Blood 1996, 88:2062-2070.
65. Murray L.J., Mandich D., Bruno E., DiGiusto R.K., Fu W.C., Sutherland D.R., Hoffman R., Tsukamoto A. Fetal bone marrow CD34+CD41+ cells are enriched for multipotent hematopoietic progenitors, but not for pluripotent stem cells. Exp. Hematol. 1996, 24:236-245.
66. Berlanga O., Emambokus N., Frampton J. GPIIb (CD41) integrin is expressed on mast cells and influences their adhesion properties. Exp. Hematol. 2005, 33:403-412.
67. Debili N., Issaad C., Masse J.M., Guichard J., Katz A., Breton-Gorius J., Vainchenker W. Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation. Blood 1992, 80:3022-3035.
68. Sprandio J.D., Shapiro S.S., Thiagarajan P., McCord S. Cultured human umbilical vein endothelial cells contain a membrane glycoprotein immunologically related to platelet glycoprotein Ib. Blood 1988, 71:234-237.
69. Konkle B.A., Shapiro S.S., Asch A.S., Nachman R.L. Cytokine-enhanced expression of glycoprotein Ib alpha in human endothelium. J. Biol. Chem. 1990, 265:19833-19838.
70. Wu G., Essex D.W., Meloni F.J., Takafuta T., Fujimura K., Konkle B.A., Shapiro S.S. Human endothelial cells in culture and in vivo express on their surface all four components of the glycoprotein Ib/IX/V complex. Blood 1997, 90:2660-2669.
71. Monteiro M.R., Shapiro S.S., Takafuta T., Menezes D.W., Murphy G.F. Von Willebrand factor receptor GPIb alpha is expressed by human factor XIIIa-positive dermal dendrocytes and is upregulated by mast cell degranulation. J. Invest. Dermatol. 1999, 113:272-276.
72. Oleksowicz L., Dutcher J.P., DeLeon-Fernandez M., Etkind P. A GPIb alpha-related protein is expressed by fresh human breast carcinoma tissue and is regulated by a PKC-sensitive mechanism. Exp. Cell Res. 1997, 237:110-117.
73. Pennacchio L.A., Rubin E.M. Genomic strategies to identify mammalian regulatory sequences. Nat. Rev. Genet. 2001, 2:100-109.
74. Lewis P.F., Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 1994, 68:510-516.
75. Miller D.G., Adam M.A., Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 1990, 10:4239-4242.
76. Bukrinsky M.I., Haggerty S., Dempsey M.P., Sharova N., Adzhubel A., Spitz L., Lewis P., Goldfarb D., Emerman M., Stevenson M. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993, 365:666-669.
77. Bukrinsky M.I., Sharova N., McDonald T.L., Pushkarskaya T., Tarpley W.G., Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc. Natl Acad. Sci. USA 1993, 90:6125-6129.
78. Zennou V., Petit C., Guetard D., Nerhbass U., Montagnier L., Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000, 101:173-185.
79. Bester A.C., Schwartz M., Schmidt M., Garrigue A., Hacein-Bey-Abina S., Cavazzana-Calvo M., Ben-Porat N. K. C. von, A. Fischer, and B. Kerem, Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther. 2006, 13:1057-1059.
80. De P.M., Montini E., Santoni de Sio F.R., Benedicenti F., Gentile A., Medico E., Naldini L. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 2005, 105:2307-2315.
81. Neschadim A., McCart J.A., Keating A., Medin J.A. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2007, 13:1407-1416.
82. Fang J., Jensen E.S., Du L.M., Boudreaux M.K., Wilcox D.A. Intravenous Immunoglobulin (IVIG) Diminishes Immune-Mediated Clearance of Platelets Expressing an Integrin {alpha}IIb{beta}3 Transgene Product That Restores Hemostasis in a Canine Model for Glanzmann Thrombasthenia. ASH Annual Meeting Abstracts 2006, 108:3263.
83. BERNARD J., SOULIER J.P. Sur une nouvelle variet e de dystrophie thrombocytarie-hemorragipare congenitale. Sem. Hôp. 1948, 24:3217-3223.
84. Balduini C.L., Iolascon A., Savoia A. Inherited thrombocytopenias: from genes to therapy. Haematologica 2002, 87:860-880.
85. Ware J., Russell S., Ruggeri Z.M. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc. Natl Acad. Sci. USA 2000, 97:2803-2808.
86. Abshire T., Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J. Thromb. Haemost. 2004, 2:899-909.
87. Yoshioka A., Shima M., Fukutake K., Takamatsu J., Shirahata A. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001, 7:242-249.
88. Kreuz W., Gill J.C., Rothschild C., Manco-Johnson M.J., Lusher J.M., Kellermann E., Gorina E., Larson P.J. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb. Haemost. 2005, 93:457-467.
89. Bohn R.L., Aledort L.M., Putnam K.G., Ewenstein B.M., Mogun H., Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004, 10:63-68.
90. Berntorp E., Archey W., Auerswald G., Federici A.B., Franchini M., Knaub S., Kreuz W., Lethagen S., Mannucci P.M., Pollmann H., Scharrer I., Hoots K. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance. Eur. J. Haematol. Suppl. 2008, 3-35.
91. Ballal R.D., Botteman M.F., Foley I., Stephens J.M., Wilke C.T., Joshi A.V. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr. Med. Res. Opin. 2008, 24:753-768.
92. Ananyeva N.M., Lacroix-Desmazes S., Hauser C.A., Shima M., Ovanesov M.V., Khrenov A.V., Saenko E.L. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul. Fibrinolysis 2004, 15:109-124.
93. Sharathkumar A., Lillicrap D., Blanchette V.S., Kern M., Leggo J., Stain A.M., Brooker L., Carcao M.D. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J. Thromb. Haemost. 2003, 1:1228-1236.
94. Key N.S. Inhibitors in congenital coagulation disorders. Br. J. Haematol. 2004, 127:379-391.
95. White G.C., McMillan C.W., Blatt P.M., Roberts H.R. Factor VIII inhibitors: a clinical overview. Am. J. Hematol. 1982, 13:335-342.
96. Scandella D.H. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin. Thromb. Hemost. 2000, 26:137-142.
97. Furie B., Limentani S.A., Rosenfield C.G. A practical guide to the evaluation and treatment of hemophilia. Blood 1994, 84:3-9.
98. Shi Q., Fahs S.A., Wilcox D.A., Weiler H., Haberichter S.L., Montgomery R.R. Endothelial and platelet FVIII/VWF expression divergence in clinical effect in murine models of hemophilia a with and without FVIII inhibitory antibodies. Blood 2006, 108:938a.
99. Chuah M.K., Brems H., Vanslembrouck V., Collen D., Vandendriessche T. Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum. Gene Ther. 1998, 9:353-365.
100. Wise R.J., Dorner A.J., Krane M., Pittman D.D., Kaufman R.J. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J. Biol. Chem. 1991, 266:21948-21955.
101. Kaufman R.J., Pipe S.W. Regulation of factor VIII expression and activity by von Willebrand factor. Thromb. Haemost. 1999, 82:201-208.
102. Weiss H.J., Hoyer I.W. Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity. Science 1973, 182:1149-1151.
103. Roth D.A., Tawa N.E., O'Brien J.M., Treco D.A., Selden R.F. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J. Med. 2001, 344:1735-1742.
104. Powell J.S., Ragni M.V., White G.C., Lusher J.M., Hillman-Wiseman C., Moon T.E., Cole V., Ramanathan-Girish S., Roehl H., Sajjadi N., Jolly D.J., Hurst D. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003, 102:2038-2045.
105. Chuah M.K., Collen D., Vandendriessche T. Clinical gene transfer studies for hemophilia A. Semin. Thromb. Hemost. 2004, 30:249-256.
106. Wagner D.D. Cell biology of von Willebrand factor. Annu. Rev. Cell Biol. 1990, 6:217-246.
107. Nachman R., Levine R., Jaffe E.A. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J. Clin. Invest. 1977, 60:914-921.
108. Jaffe E.A., Hoyer L.W., Nachman R.L. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J. Clin. Invest. 1973, 52:2757-2764.
109. Wagner D.D. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb. Haemost. 1993, 70:105-110.
110. Xu L., Nichols T.C., Sarkar R., McCorquodale S., Bellinger D.A., Ponder K.P. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc. Natl Acad. Sci. USA 2005, 102:6080-6085.
111. Horita K., Matsunami H., Shimizu Y., Shimizu A., Kurimoto M., Suzuki K., Tsukadaira T., Arai M. Treatment of a patient with hemophilia A and hepatitis C virus-related cirrhosis by living-related liver transplantation from an obligate carrier donor. Transplantation 2002, 73:1909-1912.
112. Lamont P.A., Ragni M.V. Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation. J. Thromb. Haemost. 2005, 3:2259-2263.
113. Do H., Healey J.F., Waller E.K., Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J. Biol. Chem. 1999, 274:19587-19592.
114. Montgomery R.R., Gill J.C. Interactions between von Willebrand factor and Factor VIII: where did they first meet. J. Pediatr. Hematol. Oncol. 2000, 22:269-275.
115. Shahani T., Lavend'homme R., Luttun A., Saint-Remy J.M., Peerlinck K., Jacquemin M. Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool. Blood 2010, 115:4902-4909.
116. Jacquemin M., Neyrinck A., Hermanns M.I., Lavend'homme R., Rega F., Saint-Remy J.M., Peerlinck K., Van R.D., Kirkpatrick C.J. FVIII production by human lung microvascular endothelial cells. Blood 2006, 108:515-517.
117. Kaufman R.J., Wasley L.C., Dorner A.J. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 1988, 263:6352-6362.
118. Kaufman R.J., Wasley L.C., Davies M.V., Wise R.J., Israel D.I., Dorner A.J. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol. Cell. Biol. 1989, 9:1233-1242.
119. Shi Q., Fahs S.A., Wilcox D.A., Kuether E.L., Morateck P.A., Mareno N., Weiler H., Montgomery R.R. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood 2008, 112:2713-2721.
120. Yarovoi H., Nurden A.T., Montgomery R.R., Nurden P., Poncz M. Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII. Blood 2005, 105:4674-4676.
121. Gewirtz J., Thornton M.A., Rauova L., Poncz M. Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J. Thromb. Haemost. 2008, 6:1160-1166.
122. Neyman M., Gewirtz J., Poncz M. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots. Blood 2008, 112:1101-1108.
123. Shi Q., Kuether E.L., Cooley B.C., Fahs S.A., Schroeder J.A., Wilcox D.A., Montgomery R.R. Sustained Phenotypic Correction of Murine Hemophilia A with Pre-Existing Anti-FVIII Immunity Using Lentivirus-Mediated Platelet-Specific FVIII Gene Transfer. ASH Annual Meeting Abstracts 2009, 114:29.
124. Du L.M., Nichols T.C., Haberichter S.L., Jacobi P.M., Jensen E.S., Fang J., Shi Q., Montgomery R.R., Wilcox D.A. Platelet-Targeted Expression of Human BDD-FVIII Reduces Bleeding in Canine Hemophilia A. ASH Annual Meeting Abstracts 2009, 114:691.
125. Warrier I., Lusher J.M. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul. Fibrinolysis 1998, 9(Suppl 1):S125-S128.
126. Astermark J. Treatment of the bleeding inhibitor patient. Semin. Thromb. Hemost. 2003, 29:77-86.
127. Lusher J.M. Inhibitor antibodies to factor VIII and factor IX: management. Semin. Thromb. Hemost. 2000, 26:179-188.
128. Kay M.A., Rothenberg S., Landen C.N., Bellinger D.A., Leland F., Toman C., Finegold M., Thompson A.R., Read M.S., Brinkhous K.M. and., In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993, 262:117-119.
129. Herzog R.W., High K.A. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy. Thromb. Haemost. 1999, 82:540-546.
130. Nathwani A.C., Davidoff A.M., Hanawa H., Hu Y., Hoffer F.A., Nikanorov A., Slaughter C., Ng C.Y., Zhou J., Lozier J.N., Mandrell T.D., Vanin E.F., Nienhuis A.W. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002, 100:1662-1669.
131. Chao H., Walsh C.E. AAV vectors for hemophilia B gene therapy Mt. Sinai. J. Med. 2004, 71:305-313.
132. Niemeyer G.P., Herzog R.W., Mount J., Arruda V.R., Tillson D.M., Hathcock J., van Ginkel F.W., High K.A., Lothrop C.D. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009, 113:797-806.
133. Hasbrouck N.C., High K.A. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther. 2008, 15:870-875.
134. Chang A.H., Stephan M.T., Lisowski L., Sadelain M. Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Mol. Ther. 2008, 16:1745-1752.
135. Bigger B.W., Siapati E.K., Mistry A., Waddington S.N., Nivsarkar M.S., Jacobs L., Perrett R., Holder M.V., Ridler C., Kemball-Cook G., Ali R.R., Forbes S.J., Coutelle C., Wright N., Alison M., Thrasher A.J., Bonnet D., Themis M. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther. 2006, 13:117-126.
136. Xu L., O'Malley T., Sands M.S., Wang B., Meyerrose T., Haskins M.E., Ponder K.P. In vivo transduction of hematopoietic stem cells after neonatal intravenous injection of an amphotropic retroviral vector in mice. Mol. Ther. 2004, 10:37-44.
137. Manno C.S., Chew A.J., Hutchison S., Larson P.J., Herzog R.W., Arruda V.R., Tai S.J., Ragni M.V., Thompson A., Ozelo M., Couto L.B., Leonard D.G., Johnson F.A., McClelland A., Scallan C., Skarsgard E., Flake A.W., Kay M.A., High K.A., Glader B. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003, 101:2963-2972.
138. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., Ozelo M.C., Hoots K., Blatt P., Konkle B., Dake M., Kaye R., Razavi M., Zajko A., Zehnder J., Rustagi P.K., Nakai H., Chew A., Leonard D., Wright J.F., Lessard R.R., Sommer J.M., Tigges M., Sabatino D., Luk A., Jiang H., Mingozzi F., Couto L., Ertl H.C., High K.A., Kay M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12:342-347.
139. Murphy S.L., High K.A. Gene therapy for haemophilia. Br. J. Haematol. 2008, 140:479-487.
140. High K.A. Update on progress and hurdles in novel genetic therapies for hemophilia. Hematology Am. Soc. Hematol. Educ. Program 2007, 2007:466-472.
141. Ponder K.P. Gene therapy for hemophilia. Curr. Opin. Hematol. 2006, 13:301-307.
142. Rabellino E.M., Levene R.B., Leung L.L., Nachman R.L. Human megakaryocytes. II. Expression of platelet proteins in early marrow megakaryocytes. J. Exp. Med. 1981, 154:88-100.
143. Roth G.J., Yagi M., Bastian L.S. The platelet glycoprotein Ib-V-IX system: regulation of gene expression. Stem Cells 1996, 14 Suppl 1:188-193.
144. Jandrot-Perrus M., Busfield S., Lagrue A.H., Xiong X., Debili T., Chickering T., Le Couedic J.P., Goodearl A., Dussault B., Fraser C., Vainchenker W., Villeval J.L. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000, 96:1798-1807.
145. Doi T., Greenberg S.M., Rosenberg R.D. Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation. Mol. Cell Biol. 1987, 7:898-904.
146. Uzan G., Prandini M.H., Berthier R. Regulation of gene transcription during the differentiation of megakaryocytes. Thromb. Haemost. 1995, 74:210-212.
147. Sun B., Tao L., Lin S., Calingasan N.Y., Li J.J., Tandon N.N., Yoshitake M., Kambayashi J. Expression of glycoprotein VI in vascular endothelial cells. Platelets 2003, 14:225-232.
148. Cardier J.E., Dempsey J. Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells. Blood 1998, 91:923-929.